Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: Protection against Bordetella pertussis challenge in neonates

Ivan P. Nascimento, Waldely O. Dias, Wagner Quintilio, Tsungda Hsu, William R. Jacobs, Luciana C.C. Leite

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Δlysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-ΔlysA-S1PT-lysA+(kan-), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice.

Original languageEnglish (US)
Pages (from-to)7346-7351
Number of pages6
JournalVaccine
Volume27
Issue number52
DOIs
StatePublished - Dec 9 2009

Fingerprint

Bordetella pertussis
whooping cough
Whooping Cough
Mycobacterium bovis
lysine
neonates
Lysine
antigens
Antigens
Mycobacterium bovis BCG
pertussis toxin
antigen presentation
Heterophile Antigens
cell-mediated immunity
clinical trials
Pertussis Toxin
Antigen Presentation
antibiotics
promoter regions
Cellular Immunity

Keywords

  • Auxotroph
  • Complementation
  • Neonates
  • Pertussis
  • Recombinant BCG
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation : Protection against Bordetella pertussis challenge in neonates. / Nascimento, Ivan P.; Dias, Waldely O.; Quintilio, Wagner; Hsu, Tsungda; Jacobs, William R.; Leite, Luciana C.C.

In: Vaccine, Vol. 27, No. 52, 09.12.2009, p. 7346-7351.

Research output: Contribution to journalArticle

Nascimento, Ivan P. ; Dias, Waldely O. ; Quintilio, Wagner ; Hsu, Tsungda ; Jacobs, William R. ; Leite, Luciana C.C. / Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation : Protection against Bordetella pertussis challenge in neonates. In: Vaccine. 2009 ; Vol. 27, No. 52. pp. 7346-7351.
@article{35798c4fdeb54a5385d31d518fa0449a,
title = "Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: Protection against Bordetella pertussis challenge in neonates",
abstract = "Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Δlysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-ΔlysA-S1PT-lysA+(kan-), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice.",
keywords = "Auxotroph, Complementation, Neonates, Pertussis, Recombinant BCG, Vaccine",
author = "Nascimento, {Ivan P.} and Dias, {Waldely O.} and Wagner Quintilio and Tsungda Hsu and Jacobs, {William R.} and Leite, {Luciana C.C.}",
year = "2009",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2009.09.043",
language = "English (US)",
volume = "27",
pages = "7346--7351",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation

T2 - Protection against Bordetella pertussis challenge in neonates

AU - Nascimento, Ivan P.

AU - Dias, Waldely O.

AU - Quintilio, Wagner

AU - Hsu, Tsungda

AU - Jacobs, William R.

AU - Leite, Luciana C.C.

PY - 2009/12/9

Y1 - 2009/12/9

N2 - Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Δlysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-ΔlysA-S1PT-lysA+(kan-), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice.

AB - Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Δlysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-ΔlysA-S1PT-lysA+(kan-), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice.

KW - Auxotroph

KW - Complementation

KW - Neonates

KW - Pertussis

KW - Recombinant BCG

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=70649108720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649108720&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.09.043

DO - 10.1016/j.vaccine.2009.09.043

M3 - Article

C2 - 19782111

AN - SCOPUS:70649108720

VL - 27

SP - 7346

EP - 7351

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -